The Divergence of Moats: Physical Infrastructure, Strategic Pivots, and Survival MechanicsGlobal Report·Jul 19 at 04:12 AMWU-68.00%NAK+563.00%
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 TrajectoryGlobal Report·Jul 18 at 04:13 AMAMGN+457.00%CRSP-117.00%
Market Signals Point to Growing Divergence in US Small-Cap SectorGlobal Report·Jul 17 at 04:12 AMYSXT+645.00%DWSN-674.00%
The tech fringes of 2026: AI lending, EV retreats, and the challengers still hanging onGlobal Report·Jul 15 at 04:14 AMILLR-417.00%EMR+229.00%
Mixed Signals from Micro Data: How U.S. Equities Are Navigating Sector DivergenceGlobal Report·Jul 14 at 06:47 AMTMDE-255.00%TDOC+328.00%
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-FreeTradingView·May 18 at 05:53 AMBCAB-75.00%CNTX+1145.00%
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock NewsStockTitan·May 17 at 09:45 PMCNTX+1145.00%BCAB-75.00%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·Apr 27 at 04:05 PMTRVI-53.00%ADVB-63.00%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Apr 15 at 04:05 PMCDNA-338.00%VVOS-2631.00%
NCAB Group Sets April 23 Date for First-Quarter 2026 Results PresentationTip Ranks·Apr 8 at 03:38 AMXBI+74.00%BBH+118.00%
NCAB Group Calls 2026 AGM With Expanded Voting Options for ShareholdersTip Ranks·Apr 7 at 10:24 AMIBBQ+67.00%LABU+248.00%
